17,261 trials
End-Stage Renal Disease · Kidney Failure
Primary: Composite Endpoint of 5 Components: Fever, Hypoxia, Hypotension, Cardiac Events, and Delayed Graft Function — 13; 12 participants — p=0.64
Acute Respiratory Failure
Primary: Tolerability of NIV as Assessed by an NIV Tolerance Score — 99; 67 percentage of time spent tolerant to NIV — p=0.54
Alagille Syndrome
Primary: Change From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level — -82.864; -49.388; -66.126; -42.157 umol/L — p=0.5740
Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants Who Were Histologic Responders — 2.6; 38.8 percent of participants — p=<0.0001
Lymphoma · B-cell Non-Hodgkin's Lymphoma
Primary: Improve the Overall Response Rate — 4; 2; 7; 4 participants
Hepatocellular Carcinoma
Primary: Overall Survival - Overall Survival — 33; 39.4 Weeks
Prostatic Neoplasms
Primary: Progression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment — 15.7; 5.8 months — p=<0.0001
Major Depressive Disorder
Primary: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score. — -6.62; -6.46…
Presbyopia
Primary: Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye — 46.7; 70.6; 56.3; 68.8…
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 53 percentage of participants
Major Depressive Disorder · Depression · Depressive Symptoms
Primary: Change in Brachial Flow-Mediated Dilation (FMD) From Pre- to Post- Treatment — -1.18; 0.79 % change in brachial diameter — p=.474
Multiple Myeloma
Primary: Best Overall Response Rate (ORR) in the Response Evaluable Subset Population — 16.1; 39.6; 53.0 percentage of participants
Myocardial Ischemia
Primary: Cardiac Magnetic Resonance (CMRs) — 11.7; 16.0 Percentage of ischemic myocardium
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.79; -1.87; -1.84 percentage of glycosylated haemoglobin
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Pathologic Complete Response Rates — 8 participants